On Sept. 22, 2000, Pathogenesis was acquired by Emeryville, California-based Chiron for $660 million or $38.50 per share.

PathoGenesis, founded by Robert Nowinsk in 1992, developed an inhaled antibiotic to treat lung infections in people with cystic fibrosis. In 2006, Chiron was acquired by Novartis.

In 2013, the FDA approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa.